Aurinia Pharmaceuticals (AUPH) has released an update.
Aurinia Pharmaceuticals Inc. announced that their drug LUPKYNIS is a cost-effective treatment for lupus nephritis, comparable in value to treatments for other chronic conditions. Revealed at the National Kidney Foundation’s Spring Clinical Meeting, the drug’s cost-effectiveness is supported by an updated analysis, including a favorable cost per quality adjusted life year. The findings are particularly significant for Black, Hispanic, and Latino patients, who are disproportionately affected by lupus nephritis.
For further insights into AUPH stock, check out TipRanks’ Stock Analysis page.
